{"nctId":"NCT03569891","briefTitle":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","startDateStruct":{"date":"2018-06-27","type":"ACTUAL"},"conditions":["Hemophilia B"],"count":67,"armGroups":[{"label":"AMT-061","type":"EXPERIMENTAL","interventionNames":["Genetic: AAV5-hFIXco-Padua"]},{"label":"FIX replacement (Lead-in Period)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Factor IX (FIX)"]}],"interventions":[{"name":"AAV5-hFIXco-Padua","otherNames":["AMT-061","etranacogene dezaparvovec"]},{"name":"Factor IX (FIX)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male\n2. Age ≥18 years\n3. Subjects with congenital hemophilia B, classified as severe or moderately severe, and are currently on factor IX prophylaxis\n4. \\>150 previous exposure days of treatment with factor IX protein\n\nExclusion Criteria:\n\n1. History of factor IX inhibitors\n2. Positive factor IX inhibitor test at screening\n3. Select screening laboratory value \\>2 times upper limit of normal\n4. Positive human immunodeficiency virus (HIV) test at screening, not controlled with anti-viral therapy\n5. Active infection with hepatitis B or C virus at screening\n6. History of Hepatitis B or C exposure, currently controlled by antiviral therapy at the end of the lead-in phase\n7. Previous gene therapy treatment\n8. Receipt of an experimental agent within 60 days prior to screening\n9. Current participation or anticipated participation within one year after study drug administration in this trial in any other interventional clinical trial involving drugs or devices","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Bleeding Rate (ABR) for All Bleeding Episodes","description":"ABR was calculated as the ratio of the number of bleeds to the number of days in the time interval multiplied by 365.25.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":null},{"groupId":"OG001","value":"1.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Factor IX Activity Levels After AMT-061 Dosing","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1.19","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"38.95","spread":"18.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"41.48","spread":"21.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"36.90","spread":"21.40"}]}]}]},{"type":"SECONDARY","title":"Annualized Exogenous Factor IX Consumption","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"257,338.8","spread":"149,013.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"12,912.9","spread":"37,093.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"8399.1","spread":"29,720.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"8486.6","spread":"28,770.2"}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Infusion Rate of FIX Replacement Therapy","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects Who Discontinued FIX Prophylaxis and Remained Free of Routine FIX Prophylaxis After AMT-061 Dosing","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Trough FIX Activity <12% of Normal","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"ABR for FIX-treated Bleeding Episodes","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Spontaneous Bleeding Episodes","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Joint Bleeding Episodes","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean FIX Activity (%) in Subjects With Pre-Existing Neutralizing Antibodies to AAV5 After AMT-061 Dosing","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1.24","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"35.91","spread":"19.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"35.54","spread":"17.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"31.14","spread":"13.75"}]}]}]},{"type":"SECONDARY","title":"Mean FIX Activity (%) in Subjects Without Pre-Existing Neutralizing Antibodies to AAV5 After AMT-061 Dosing","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1.15","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"40.61","spread":"18.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"44.82","spread":"23.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"39.87","spread":"24.08"}]}]}]},{"type":"SECONDARY","title":"Number of New Target Joints and the Number of New Target Joints Resolved.","description":"A target joint was defined as 3 or more spontaneous bleeding episodes into a single joint within a consecutive 6-month period prior to the dosing visit and which was not resolved by the time of dosing. An identified target joint with ≤2 spontaneous bleeding episodes within a consecutive 12-month period was considered resolved.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Zero Bleeding Episodes During the 52 Weeks Following Stable FIX Expression (6 to 18 Months) After AMT-061 Dosing","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"63.0","spread":null}]}]}]},{"type":"SECONDARY","title":"International Physical Activity Questionnaire (iPAQ) Overall Score","description":"The iPAQ was designed to provide an evaluation of daily physical activities in metabolic equivalent of task (MET) minutes/week. To calculate MET minutes a week multiply the MET value given (walking = 3.3, moderate activity = 4, vigorous activity = 8) by the minutes the activity was carried out and again by the number of days that that activity was undertaken. A higher score is considered to be more favorable.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4548.1","spread":"512.38"},{"groupId":"OG001","value":"3826.9","spread":"480.44"}]}]}]},{"type":"SECONDARY","title":"EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) VAS Overall Score","description":"The EQ-5D-5L descriptive system of health-related QoL states consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). The EQ-5D-5L VAS overall score ranges from 0 to 100. A higher score is considered to be more favorable.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":"2.20"},{"groupId":"OG001","value":"81.0","spread":"2.15"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"Follow up and assess any adverse events reported for safety","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":67},"commonTop":["Nasopharyngitis","Arthralgia","Headache","Fatigue","Oropharyngeal pain"]}}}